- Home
- GAU vs REPL Comparison
GAU vs REPL Comparison
Compare GAU & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | REPL |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.3M | 781.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GAU | REPL |
|---|---|---|
| Price | $3.10 | $7.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.5M |
| Earning Date | 02-12-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $352,642,000.00 | N/A |
| Revenue This Year | $82.50 | N/A |
| Revenue Next Year | $57.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 111.43 | N/A |
| 52 Week Low | $1.00 | $2.68 |
| 52 Week High | $3.26 | $14.80 |
Technical Indicators
Market Signals| Indicator | GAU | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 64.65 | 37.95 |
| Support Level | $2.86 | $7.39 |
| Resistance Level | $3.26 | $7.91 |
| Average True Range (ATR) | 0.15 | 0.53 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 74.67 | 28.27 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.